Jubilant Pharmova Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 16,652 million compared to INR 15,332 million a year ago. Revenue was INR 17,129 million compared to INR 15,620 million a year ago. Net income was INR 668 million compared to net loss of INR 156 million a year ago. Basic earnings per share from continuing operations was INR 4.22 compared to basic loss per share from continuing operations of INR 0.98 a year ago. Diluted earnings per share from continuing operations was INR 4.2 compared to diluted loss per share from continuing operations of INR 0.98 a year ago.
For the nine months, sales was INR 48,984 million compared to INR 45,584 million a year ago. Revenue was INR 49,986 million compared to INR 46,376 million a year ago. Net income was INR 1,357 million compared to INR 369 million a year ago. Basic earnings per share from continuing operations was INR 8.56 compared to INR 2.32 a year ago. Diluted earnings per share from continuing operations was INR 8.54 compared to INR 2.32 a year ago.